TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products

Size: px
Start display at page:

Download "TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products"

Transcription

1 TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification 2.7 Prognosis 2.8 Diagnosis 2.9 Assessing Treatment Effectiveness 2.10 Treatment Algorithm The Role of Insulin in Type 2 Diabetes Non-insulin Diabetic Drugs Other Drugs 3 Key Marketed Products 3.1 Metformin 3.2 DPP-4 Inhibitors Januvia (sitagliptin) Merck & Co Tradjenta (linagliptin) Boehringer Ingelheim Onglyza (saxagliptin) Bristol-Myers Squibb and AstraZeneca Nesina (alogliptin) Takeda Galvus (vildagliptin) Novartis Tenelia (teneligliptin) Daiichi Sankyo and Mitsubishi Tanabe 3.3 GLP-1 Agonists Byetta and Bydureon (exenatide) Bristol-Myers Squibb Lyxumia (lixisenatide) Sanofi Victoza (liraglutide) Novo Nordisk 3.4 Sulfonylureas Glimepiride Gliclazide 3.5 Thiazolidinediones Actos (pioglitazone) Takeda Pharmaceuticals Limited Avandia (rosiglitazone) GlaxoSmithKline 3.6 Long-Acting Insulins Lantus (insulin glargine) Sanofi Levemir (insulin detemir) Novo Nordisk Tresiba and Ryzodeg (Insulin degludec) Novo Nordisk 3.7 SGLT-2 Inhibitors Forxiga (dapagliflozin) Bristol-Myers Squibb Invokana (canagliflozin) Janssen 3.8 Heat Map for Marketed Products

2 4 Pipeline for Type 2 Diabetes 4.1 Overall Pipeline 4.2 Therapeutic Classes 4.3 Rate of Attrition Failure Rate by Molecule Type Failure Rate by Therapeutic Class 4.4 Reasons for Failure of Developmental Programs 4.5 Clinical Trial Duration Duration by Molecule Type Duration by Therapeutic Class 4.6 Clinical Trial Size Clinical Trial Size by Molecule Type Clinical Trial Size by Therapeutic Class 4.7 Promising Drugs in the Pipeline LY (dulaglutide) Eli Lilly Albiglutide GlaxoSmithKline LC (gemigliptin) LG Life Sciences TAK-875 Takeda Ipragliflozin Astellas Pharma LX-4211 Lexicon Pharmaceuticals Imeglimin Poxel SA CCX-140-B ChemoCentryx Semaglutide Novo Nordisk A/S PC-DAC Exendin-4 ConjuChem Biotechnologies 4.8 Heat Map for Pipeline Products 4.9 Conclusion 5 Market Forecast to 5.1 Global Market Treatment Usage Patterns Market Size 5.2 US Treatment Usage Patterns Annual Cost of Therapy Market Size 5.3 Top Five Countries of Europe Treatment Usage Patterns Annual Cost of Therapy Market Size 5.4 Japan Treatment Usage Patterns Annual Cost of Therapy Market Size 5.5 Drivers and Barriers Drivers Barriers

3 6 Deals and Strategic Consolidations 6.1 Licensing Deals TransTech Pharma Enters into Licensing Agreement with Forest Laboratories Xoma Enters into Licensing Agreement with Les Laboratoires Servier for Xoma Zealand Pharma Enters into a Licensing and Collaboration Agreement with Boehringer Ingelheim Exelixis Enters into Licensing Agreement with Bristol-Myers Squibb for XL Prosidion Limited Enters into a Licensing Agreement with Eli Lilly and Company Metabolex Enters into Licensing Agreement with Sanofi Wellstat Enters into a License Agreement with Sanofi CureDM and Lankenau Institute Enter into a Licensing Agreement with Sanofi Metabolex Enters into a Development and Licensing Agreement with Janssen Pharmaceuticals Dainippon Sumitomo Pharma Enters into Licensing Agreement with Intercept Pharma for INT Ipsen Enters into Licensing Agreement with F. Hoffmann-La Roche for BIM Glenmark Pharma Enters into Licensing Agreement with Merck KGaA Euroscreen Enters into Licensing Agreement with Janssen Pharmaceuticals Phenomix Enters into Licensing Agreement with Chiesi Farmaceutici Otsuka Pharma Enters into Licensing Agreement with Kyowa Hakko Kirin for Saxagliptin Nastech Pharma Enters into Licensing Agreement with Amylin Pharma Emisphere Technologies Enters into a Licensing Agreement with Novo Nordisk Array BioPharma Enters into a Licensing Agreement with Amgen Theratechnologies Enters into a Licensing Agreement with OctoPlus Diabetica Enters into a Licensing Agreement with Amylin Celtic Therapeutics Enters into a Licensing Agreement with Bellus Health Aradigm Enters into a Licensing Agreement with Novo Nordisk Santarus Enters into a License Agreement with Shore Therapeutics Depomed Enters into a Licensing Agreement with Boehringer Ingelheim Depomed Enters into a Licensing Agreement with Merck Depomed Enters into a Licensing Agreement with Teva 6.2 Co-development Deals Eli Lilly Enters into a Co-development Agreement with Boehringer Ingelheim AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb Metabolex Enters into a Co-development Agreement with Janssen Pharmaceuticals

4 6.2.4 Amylin Pharma Terminates Co-development Agreement with Eli Lilly for Exenatide Isis Enters into a Collaboration Agreement with Janssen Pharmaceuticals Neurocrine Biosciences Enters into a Collaboration Agreement with Boehringer Ingelheim Intercept Pharma Enters into Co-development Agreement with Servier Transition Therapeutics Enters into an Agreement with Eli Lilly Ambrx Enters into a Co-Development Agreement with Bristol-Myers Squibb Biocompatibles Enters into a Co-Development Agreement with AstraZeneca 7 Appendix 7.1 All Pipeline Drugs by Stage of Development Discovery Preclinical and IND-filed Phase I Phase II Phase III and Pre-registration Undisclosed 7.2 Market Forecasts to Global US UK France Germany Italy Spain Japan 7.3 Market Definitions 7.4 Abbreviations 7.5 References for Heat Maps 7.6 References 7.7 Research Methodology Coverage Secondary Research Primary Research 7.8 Therapeutic Landscape 7.9 Epidemiology-based Forecasting 7.10 Market Size by Geography 7.11 Geographical Landscape 7.12 Pipeline Analysis 7.13 Expert Panel Validation 7.14 Contact Us 7.15 Disclaimer

5 LIST OF TABLES 1.1 List of Tables Table 1: The Relationship between HbA1c and Mean Blood Glucose Table 2: Pipeline Drugs (Discovery) Table 3: Pipeline Drugs (Preclinical and IND-filed) Table 4: Pipeline Drugs (Phase I) Table 5: Pipeline Drugs (Phase II) Table 6: Pipeline Drugs (Phase III) Table 7: Pipeline Drugs (Undisclosed stage of development) Table 8: Type 2 Diabetes Therapeutics Market, Global, Market Forecast, 2012 Table 9: Type 2 Diabetes Therapeutics Market, US, Market Forecast, 2012 Table 10: Type 2 Diabetes Therapeutics Market, UK, Market Forecast, 2012 Table 11: Type 2 Diabetes Therapeutics Market, France, Market Forecast, 2012 Table 12: Type 2 Diabetes Therapeutics Market, Germany, Market Forecast, 2012 Table 13: Type 2 Diabetes Therapeutics Market, Italy, Market Forecast, 2012 Table 14: Type 2 Diabetes Therapeutics Market, Spain, Market Forecast, 2012 Table 15: Type 2 Diabetes Therapeutics Market, Japan, Market Forecast, 2012 Table 16: Type 2 Diabetes Therapeutics Market, Global, References for Heat Maps, List of Figures Figure 1: Type 2 Diabetes Therapeutics Market, Global, Composite Treatment Algorithm, 2013 Figure 2: Type 2 Diabetes Therapeutics Market, Global, Sales of Januvia and Janumet ($m), Figure 3: Type 2 Diabetes Therapeutics Market, Global, Sales of Onglyza ($m), Figure 4: Type 2 Diabetes Therapeutics Market, Global, Sales of Galvus ($m), Figure 5: Type 2 Diabetes Therapeutics Market, Global, Sales of Byetta ($m), Figure 6: Type 2 Diabetes Therapeutics Market, Global, Sales of Victoza ($m), Figure 7: Type 2 Diabetes Therapeutics Market, Global, Sales of Actos ($m), Figure 8: Type 2 Diabetes Therapeutics Market, Global, Sales of Avandia ($m), Figure 9: Type 2 Diabetes Therapeutics Market, Global, Sales of Lantus ($m),

6 Figure 10: Type 2 Diabetes Therapeutics Market, Global, Sales of Levemir (As reported by Novo Nordisk), Figure 11: Type 2 Diabetes Therapeutics Market, Global, Heat Map of Marketed Products, 2013 Figure 12: Type 2 Diabetes Therapeutics Market, Global, Sales of Novel Products ($m, Years after Approval), Figure 13: Type 2 Diabetes Therapeutics Pipeline Overview Figure 14: Type 2 Diabetes Therapeutics Market, Global, Therapeutic Classes Figure 15: Type 2 Diabetes Therapeutics Market, Global, Clinical Trial Failure Rate (%), Figure 16: Type 2 Diabetes Therapeutics Market, Global, Failure Rate by Molecule Type, Figure 17: Type 2 Diabetes Therapeutics Market, Global, Failure Rate by Therapeutic Class, Figure 18: Type 2 Diabetes Therapeutics Market, Global, Reasons for Clinical Trial Failure (%), Figure 19: Type 2 Diabetes Therapeutics Market, Global, Clinical Trial Duration, Figure 20: Type 2 Diabetes Therapeutics Market, Mean Clinical Trial Duration by Therapeutic Class, Global, Figure 21: Type 2 Diabetes Therapeutics Market, Mean and Median Clinical Trial Size, Global, Figure 22: Type 2 Diabetes Therapeutics Market, Clinical Trial Size by Molecule Type, Global, Figure 23: Type 2 Diabetes Therapeutics Market, Clinical Trial Size by Therapeutic Class, Global, Figure 24: Type 2 Diabetes Therapeutics Market, Heat Map of Pipeline Products Figure 25: Type 2 Diabetes Therapeutics Market, Global, Heat Map of Marketed Products, 2013 Figure 26: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns ( 000), 2012 Figure 27: Type 2 Diabetes Therapeutics Market, Global, Market Size ($m), 2012 Figure 28: Type 2 Diabetes Therapeutics Market, US, Treatment Usage Patterns, 2012 Figure 29: Type 2 Diabetes Therapeutics Market, Global, Market Size ($m), 2012 Figure 30: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, 2012 Figure 31: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2012 Figure 32: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Market Size ($m), 2012 Figure 33: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns, 2012

7 Figure 34: Type 2 Diabetes Therapeutics Market, Japan, Market Size ($m), 2012 Figure 35: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals by Country, Figure 36: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals, Figure 37: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals, Figure 38: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals by Country, Figure 39: Type 2 Diabetes Therapeutics Market, Global, Co-development Deals, Figure 40: GBI Research Market Forecasting Model

Current and future market dynamics overview

Current and future market dynamics overview OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast

More information

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA

More information

REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Januvia for Type 2 diabetes in the 10 major pharmaceutical markets

More information

REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 Executive Summary Fasiglifam (TAK-875): Key Metrics in the 10 Major Pharmaceutical Markets* 2022 Market Sales US $508m 5EU $127m Japan $30m China $341m

More information

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)

More information

Navigating the New Options for the Management of Type 2 Diabetes

Navigating the New Options for the Management of Type 2 Diabetes Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of

More information

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

Physician Drug Reference Chart for Diabetes Antidiabetic Medications Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset

More information

REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Empagliflozin for Type 2 diabetes in the 10 major pharmaceutical

More information

REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Albiglutide for Type 2 diabetes in the 10 major pharmaceutical

More information

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team

More information

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015 Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages

More information

Very Practical Tips for Managing Type 2 Diabetes

Very Practical Tips for Managing Type 2 Diabetes Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)

More information

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia) How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is

More information

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018 Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action

More information

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic

More information

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin) Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your

More information

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0 Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol

More information

3. Cardiovascular Disease?

3. Cardiovascular Disease? Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart

More information

Type 2 Diabetes Mellitus hypoglycaemic agents

Type 2 Diabetes Mellitus hypoglycaemic agents Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic

More information

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations 177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary

More information

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations 177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS

More information

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17 Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)

More information

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified

More information

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable

More information

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed

More information

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold

More information

Collaborative Practice Agreement

Collaborative Practice Agreement Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4

More information

TYP 2 DIABETES. Marc Donath

TYP 2 DIABETES. Marc Donath TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes

More information

Eli Lilly and Company Investment Community Meeting

Eli Lilly and Company Investment Community Meeting Eli Lilly and Company Investment Community Meeting October 3, 2013 8:30 a.m. 12:30 p.m. Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current

More information

How can we improve outcomes in Type 2 diabetes?

How can we improve outcomes in Type 2 diabetes? How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy

More information

The Death of Sulfonylureas? A Review of New Diabetes Medications

The Death of Sulfonylureas? A Review of New Diabetes Medications The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2

More information

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide

More information

What s New in Diabetes Medications. Jena Torpin, PharmD

What s New in Diabetes Medications. Jena Torpin, PharmD What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects

More information

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which

More information

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Clinical Cases in Diabetes Management. Joseph Cook D.O. Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians

More information

Drug Class Review Newer Diabetes Medications and Combinations

Drug Class Review Newer Diabetes Medications and Combinations Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms

More information

New Therapies for Diabetes

New Therapies for Diabetes Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of

More information

Search strategies key terms

Search strategies key terms Online Resource - Search strategies key terms - Table S1a,b: characteristics RCTs comparing GLP-1 with insulin - Table S2a,b: characteristics observational studies comparing DPP-4i with sulfonylurea -

More information

Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes

Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Duality Statement Dr. Reid is a Speaker and Consultant

More information

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality

More information

Disclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017

Disclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017 Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,

More information

Type 2 diabetes & Cardiovascular disease. update. Barcelona, March 15th 2018

Type 2 diabetes & Cardiovascular disease. update. Barcelona, March 15th 2018 Type 2 diabetes & Cardiovascular disease update Barcelona, March 15th 2018 Francesc Xavier Cos Claramunt Sant Martí de Provençals. Head of Innovation and Health in Barcelona city Assoc.ProfUniversitatAutonomade

More information

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the

More information

Diabetes 2016: Strategies for achieving optimal diabetes control

Diabetes 2016: Strategies for achieving optimal diabetes control PHASE Safety Net Community Benefit Diabetes 2016: Strategies for achieving optimal diabetes control Presented by: Lisa Gilliam, MD, PhD Clinical Leader Diabetes Program Kaiser Permanente Northern California

More information

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Table 1. Antihyperglycemic agents for use in type 2 diabetes Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not

More information

Update Diabetes Therapie. Marc Y Donath

Update Diabetes Therapie. Marc Y Donath Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12

More information

Welcome to the PHASE Learning Community! October 31, 2018

Welcome to the PHASE Learning Community! October 31, 2018 Welcome to the PHASE Learning Community! October 31, 2018 Webinar Housekeeping 1. Dial in for audio: 303-248-0285, Access Code: 5617817 2. Lines are muted. You can chat in questions or unmute your line

More information

Du gusts is megl che one. Edoardo Mannucci

Du gusts is megl che one. Edoardo Mannucci Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli

More information

Cardiovascular Impact of Medications for Treating Type 2 Diabetes

Cardiovascular Impact of Medications for Treating Type 2 Diabetes Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational

More information

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic

More information

1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Diabetic Foot Ulcer Therapeutics - Introduction 2.1 Overview Diabetic Foot Ulcer

1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Diabetic Foot Ulcer Therapeutics - Introduction 2.1 Overview Diabetic Foot Ulcer 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Diabetic Foot Ulcer Therapeutics - Introduction 2.1 Overview 2.1.1 Diabetic Foot Ulcer Classification Systems 2.2 Epidemiology 2.2.1 Historic

More information

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime Disclosures Current Diabetes Medications None Claire Baker, M.D. Diabetes & Endocrine Associates January 24, 2018 Objectives Identify categories of diabetes medications Understand the pharmacology of diabetes

More information

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding

More information

BRIC DIABETES DRUGS MARKET

BRIC DIABETES DRUGS MARKET BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a

More information

Pharmacologic Agents for Treatment of Type 2 Diabetes

Pharmacologic Agents for Treatment of Type 2 Diabetes Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide

More information

Oral and Injectable Non-insulin Antihyperglycemic Agents

Oral and Injectable Non-insulin Antihyperglycemic Agents Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.

More information

Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists

Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict

More information

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants

More information

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies. OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),

More information

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name

More information

Newer Therapies for Type 2 Diabetes

Newer Therapies for Type 2 Diabetes Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism

More information

Date of Review: September 2016 Date of Last Review: September 2015

Date of Review: September 2016 Date of Last Review: September 2015 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

ORAL AND INJECTABLE (NON-INSULIN) PHARMACOLOGICAL AGENTS FOR TYPE 2 DIABETES

ORAL AND INJECTABLE (NON-INSULIN) PHARMACOLOGICAL AGENTS FOR TYPE 2 DIABETES ORAL AND INJECTABLE (NON-INSULIN) PHARMACOLOGICAL AGENTS FOR TYPE 2 DIABETES Joseph L. Evans, Ph.D., President, P & N Development Ventures, Saint Louis, MO USA Email: jevansphd@earthlink.net Börk Balkan,

More information

Alia Gilani Health Inequalities Pharmacist

Alia Gilani Health Inequalities Pharmacist Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing

More information

Diabetes Treatment Guidelines

Diabetes Treatment Guidelines Diabetes Treatment Guidelines For more comprehensive information about current approaches to the diagnosis and treatment of diabetes, visit the American Diabetes Association Standards of Medical Care 2018

More information

La lezione dei trials di safety cardiovascolare. Edoardo Mannucci

La lezione dei trials di safety cardiovascolare. Edoardo Mannucci La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer

More information

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015 Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and

More information

How to Fight Diabetes and Win. Diabetes. Medications

How to Fight Diabetes and Win. Diabetes. Medications How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to

More information

Type 2 Diabetes in Practice. An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report

Type 2 Diabetes in Practice. An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report Type 2 Diabetes in Practice An Expert Commentary with Farhad Zangeneh, MD, FACP, FACE A Clinical Context Report Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and

More information

GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS

GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

Clinical Practice Guidelines

Clinical Practice Guidelines Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework

More information

Information for Patients

Information for Patients Information for Patients Guidance for Diabetic Persons having an OGD or Bronchoscopy This guidance is provided to assist with your preparation for your endoscopic procedure. If you feel unclear about how

More information

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,

More information

Diabetes Mellitus II CPG

Diabetes Mellitus II CPG 1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years

More information

Diabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust

Diabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending

More information

2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists

2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists WAYNE STATE UNIVERSITY COLLEGE OF PHARMACY & HEALTH SCIENCES FEBRUARY 28, 2016 The Evolving Armamentarium for Type 2 Diabetes: Clinical Assistant Professor, Department of Pharmacy Practice Ambulatory Care

More information

INSIGHTS PRACTICE INSULIN, PRIOR AUTHORIZATION, AND UTILIZATION MANAGEMENT DECEMBER 2017 DEVELOPED BY THE AMERICAN PHARMACISTS ASSOCIATION

INSIGHTS PRACTICE INSULIN, PRIOR AUTHORIZATION, AND UTILIZATION MANAGEMENT DECEMBER 2017 DEVELOPED BY THE AMERICAN PHARMACISTS ASSOCIATION PRACTICE DECEMBER 2017 INSIGHTS INSULIN, PRIOR AUTHORIZATION, AND UTILIZATION MANAGEMENT DEVELOPED BY THE AMERICAN PHARMACISTS ASSOCIATION SUPPORTED BY SANOFI Contents Introduction... 1 Diabetes Management

More information

Session 10: Drugs. GLP-1 receptor agonists

Session 10: Drugs. GLP-1 receptor agonists Session 10: Drugs GLP-1 receptor agonists Dr. Manel Mata La Mina Primary Health Care Centre. Barcelona. Catalonian Institute of Health. Grup DAP_Cat, Barcelona Research Support Unit. IDIAP-Jordi Gol. CIBERDEM.

More information

Advanced Practice Education Associates. Endocrine

Advanced Practice Education Associates. Endocrine Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and

More information

Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18

Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 No conflicts of interest Objectives for this talk Update on non-insulin drug therapy fro type 2 DM Appropriate use of insulin in type 2 DM ADA

More information

The Flozins Quest for Clarity?

The Flozins Quest for Clarity? The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional

More information

2018 Diabetes Summit Managing Diabetes: An Art and a Science

2018 Diabetes Summit Managing Diabetes: An Art and a Science 2018 Diabetes Summit Managing Diabetes: An Art and a Science Natasha Petry, PharmD, BCACP NDSU College of Health Professions, School of Pharmacy, Department of Pharmacy Practice Patient-Centered Medical

More information

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas

More information

Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018

Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018 Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018 RACHEL NAIDA, PHARMD, CDE CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF NEW ENGLAND COLLEGE OF PHARMACY

More information

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator

More information

John Ansell President, John Ansell Consultancy Thame, UK

John Ansell President, John Ansell Consultancy Thame, UK Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1

More information

Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c

Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c Joanna W. Chung, PharmD, BCPS; Melody L. Hartzler, PharmD, AE-C, BCACP, BC-ADM; Ashley Smith, PharmD; Jessica Hatton,

More information

3/22/2017. Type 2 Diabetes Pathophysiology and Pharmacology Review. Accreditation Statement

3/22/2017. Type 2 Diabetes Pathophysiology and Pharmacology Review. Accreditation Statement Type 2 Diabetes Pathophysiology and Pharmacology Review Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA This

More information

GLP-1RA and insulin: friends or foes?

GLP-1RA and insulin: friends or foes? Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck

More information

HYPOGLYCEMIA MANAGEMENT IN DIABETES

HYPOGLYCEMIA MANAGEMENT IN DIABETES Scenes and Seminars on HYPOGLYCEMIA MANAGEMENT IN DIABETES Multidisciplinary Approaches to Improving Safety for Patients With Diabetes FEATURING: Etie Moghissi, MD, FACP, FACE Program Chair Davida F Kruger,

More information

9/16/2013. Sherwin D Souza, M.D.

9/16/2013. Sherwin D Souza, M.D. Sherwin D Souza, M.D. Burden of disease in 2013 Type 2 DM Glucose Management Goals-understand the new guidelines by ADA/ AACE Drugs available for management of diabetes in 2013 (non insulin and insulin

More information

Exploring Non-Insulin Therapies in Type 1 Diabetes

Exploring Non-Insulin Therapies in Type 1 Diabetes Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced

More information

Non-Insulin Diabetes Medications Summary

Non-Insulin Diabetes Medications Summary Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential

More information

How they work and when to take them. Diabetes Medications

How they work and when to take them. Diabetes Medications How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most

More information

Update on Agents for Type 2 Diabetes

Update on Agents for Type 2 Diabetes Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific

More information

DR. SUBHASH K. WANGNOO

DR. SUBHASH K. WANGNOO Photograph DR. SUBHASH K. WANGNOO M.D, D.M, FRCP (London) Senior Consultant, Endocrinologist & Diabetologist Apollo Centre for Obesity, Diabetes and Endocrinology Indraprastha Apollo Hospital, Sarita Vihar,

More information

Diabetic Management of the Cardiac Patient

Diabetic Management of the Cardiac Patient Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:

More information